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Background Omalizumab is a humanized monoclonal anti-immunoglobulin E antibody, approved for the treatment of spontan-
eous chronic urticaria, with high efficacy and an excellent safety profile. Although its adverse effects are rare, aller-
gic reactions and cardiovascular events were previously described.
...................................................................................................................................................................................................
Case summary The authors describe the case of a 75-year-old woman, followed at the outpatient dermatology clinic due to spon-
taneous chronic urticaria, treated with omalizumab 300 mg every 4 weeks. After the 11th administration of
omalizumab, the patient developed an episode of thoracalgia associated with electro- and echocardiographic abnor-
malities. Coronary angiogram excluded coronary artery disease, and left ventriculography demonstrated mid-apical
akinesia and basal hyperkinesia, consistent with the Takotsubo syndrome (TS).
...................................................................................................................................................................................................
Discussion Takotsubo syndrome was already reported in association with other monoclonal antibodies. However, to our
knowledge, this is the first case of TS following the administration of omalizumab.
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Introduction
A Takotsubo syndrome (TS) is an acute, often reversible, dilated car-
diomyopathy that clinically mimics an acute myocardial infarction and
is usually associated with emotional or physical stress. There is con-
siderable evidence that sympathetic stimulation is central to its
pathogenesis, however, the precise pathophysiological mechanisms
of TS are not completely understood.
There are rare cases described that associate TS with adverse
drug reactions. This is the first known reported case of TS after ad-
ministration of omalizumab.
Learning points
• Omalizumab may be a cause of Takotsubo syndrome.
• It is of crucial importance to maintain adequate pharmacovigi-
lance in order to detect adverse drug effects at an early stage.
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A 75-year-old-woman with a history of Type 2 diabetes, hyperten-
sion, dyslipidaemia, and hypothyroidism was being followed up by the
dermatology team for spontaneous chronic urticaria resistant to oral
antihistamines, which was controlled with four weekly subcutaneous
omalizumab 300 mg (Urticaria Activity Score Over 7 Days of 5).
Thirty minutes after the 11th administration of omalizumab, the pa-
tient complained of oppressive chest pain, lasting 30 min, without radi-
ation, and no other associated symptomatology. On physical
examination, she was hypertensive with blood pressure of 190/
80 mmHg and heart rate of 70 b.p.m. Cardiac auscultation revealed pres-
ence of S1, S2, and S4 with no murmurs noted and lung auscultation was
normal. The rest of the physical examination was unremarkable, namely
with no other signs of heart failure, angioedema, or cutaneous lesions.
An electrocardiogram (EKG) was performed, showing a left anter-
ior fascicular block de novo, besides the complete right bundle branch
block already present. The 30-min EKG evolved with deep inversion
of the V2–V6 T wave and loss of R waves in these leads (Figure 1).
Laboratory tests showed troponin T values of 535 ng/dL (normal
<14 ng/dL), creatine kinase-muscle/brain (CK-MB) of 248 U/L (nor-
mal <192 ng/dL), and C-reactive protein of 4.9 mg/dL (normal
<0.5 mg/dL), without other significant changes.
A transthoracic echocardiogram was remarkable for akinesia of all
the medial and apical segments of the left ventricle with apical bal-
looning, sparing the base of each wall, causing a reduced ejection
fraction of 30%. The patient was administered loading doses of aspirin
and clopidogrel and underwent coronary angiography, which
excluded significant coronary artery disease. Ventriculography
showed the existence of extensive mid-apical akinesia and basal
hyperkinesia and confirmed the diagnosis of TS (Figure 2).
The patient was admitted to the cardiology ward for monitoring.
Bisoprolol and ramipril were started at low dose and uptitrated.
The hospitalization was uneventful, with normalization of troponin,
CK-MB levels, and inflammatory markers at Day 8. Repeat trans-
thoracic echocardiography showed a global left ventricular ejection
fraction of 56% at time of discharge. Serum and urinary catechol-
amines were not increased. Myocardial scintigraphy identified a
decreased myocardial 123I-meta-iodobenzylguanidine (MIBG) uptake
in the lateral, inferolateral and apical walls, suggesting cardiac adren-
ergic nervous dysfunction (Figure 3). A low late heart-to-mediastinum
ratio and a high washout rate were documented, a pattern usually
observed in MIBG imaging in TS. The patient was discharged with
bisoprolol 5 mg and ramipril 2.5 mg in addition to the previous medi-
cations. Omalizumab was discontinued.
The patient was evaluated 1 month after hospital discharge and
the cardiac MRI performed at this time was normal (namely without
alterations of the segmental contractility and a left ventricular ejec-
tion fraction of 66%), demonstrating the transient behaviour and
complete resolution of this pathology.
Urticaria symptoms remained well controlled with oral antihist-
amines, after omalizumab withdrawal.
Discussion
Takotsubo syndrome is included in non-classified non-familial car-
diomyopathies1 and represents between 1.7% and 2.2% of
patients with suspected acute coronary syndrome.2 The patho-
physiology of TS has not been fully elucidated, although the most
accepted mechanism is a catecholaminergic excess,3–5 which in
turn causes microvascular dysfunction at the level of the coronary
arteries causing vasospasm and transient decrease of blood flow
to the myocardium, responsible for the dysfunction of ventricular
segmental contractility. In fact, most reported cases are associated
with sympathetic triggers such as the typical emotional or physical
stress. However, there is increasing evidence that the pathophysi-
ology of this disease may be more complex, involving direct myo-
cardial injury.
In this case, and according to the new 2015 Heart failure
Association of the European Society of Cardiology Takotsubo
Syndrome Diagnostic criteria,6 the diagnosis of TS was made based
on the evidence of left ventricular mid and apical segments akinesis
with apical ballooning; new electrocardiogram abnormalities; posi-
tive but relatively small elevation in cardiac troponins; absence of sig-
nificant coronary artery disease or plaque rupture on angiograph; and
recovery of ventricular systolic function on cardiac imaging at follow-
up. An InterTAK Diagnostic Score7 of 43 [female sex 25 points, ab-
sence of ST-segment depression (except in lead aVR) 12 points, and
QTc prolongation 6 points] was suggestive of TS.
One may hypothesize about risk factors predisposing this patient
to TS. In fact, TS most frequently affects older and post-menopausal
women.8 Women above the age of 55 seem to have a five-fold
September 2016 Diagnosis of chronic urticaria resistant to oral anti-
histamines and initiation of medication with
omalizumab
26 July 2017 Admitted to the hospital to have the 11th adminis-
tration of omalizumab
Thirty minutes later, the patient complained of op-
pressive chest pain
Electrocardiogram showed alterations of
repolarization
Transthoracic echocardiogram showed mid-apical
akinesia of the left ventricle with apical balloon-
ing and reduced ejection fraction of 30%
Coronary angiogram excluded atherosclerotic cor-
onary disease
31 July 2017 Cardiac meta-iodobenzylguanidine (MIBG) scintig-
raphy showed decreased myocardial 123I-MIBG
uptake in the lateral, inferolateral, and apical
walls
All the investigations suggested Takotsubo
syndrome
3 August 2017 Full recovery and discharge
August 2017 Cardiac MRI showed complete resolution
February 2018 Last follow-up. Patient in good clinical condition




































..increased risk of developing TS than younger females.9 Reduced oes-
trogen levels in menopausal women may render the heart more vul-
nerable to catechomaninergic stress, explaining the higher frequency
of TS in this population.10 Further studies are needed to better
understand these associations.
After excluding the most frequent triggers, including previous his-
tory of emotional or physical stress, the administration of omalizu-
mab appeared to be the main triggering factor of TS in this case.
Indeed, TS has been increasingly associated with adverse drug
events,11 even though none so far has described the association with
omalizumab.
Omalizumab is a monoclonal antibody that binds selectively to
serum free immunoglobulin E, avoiding binding to its receptors and
consequently inhibiting the inflammatory response induced by aller-
gens, so is an effective drug in severe asthma and chronic spontan-
eous urticaria.12
Observational studies,13 which included patients with moderate to
severe asthma treated with omalizumab and a control group, showed
that patients receiving this monoclonal antibody had a higher inci-
dence at 5 years of cardiovascular events (acute myocardial
infarction, unstable angina, transient ischaemic stroke, and cerebral
thromboembolism), although cardiovascular death was similar in
both groups. These adverse effects were not confirmed in subse-
quent studies.14,15 Regarding these controversies, coupled with study
limitations such as baseline discrepancies in asthma severity and car-
diovascular risk factors between the two groups, as well as the ele-
vated dropout rate, further evidence is needed to definitively confirm
the cardiovascular risk and safety profile of omalizumab.
There are reported cases of TS secondary to the administration of
several other monoclonal antibodies used in oncology such as rituxi-
mab,16–18 bevacizumab,19 transtuzumab,20 and cetuximab.21 The oc-
currence of TS was in these cases attributed more often to
cardiotoxic direct effect, mostly via free radicals-induced cardiac
myocyte damage and death.17 However, other pathophysiological
hypotheses were raised as a paraneoplastic phenomenon or stress
associated with neoplasia.
A recent review examined 15711 published cases of drug-
dependent TS and showed that 68.2% of the cases were associated
with excess catecholamines [either by exogenous administration
(36.2%) or by drugs with a potential adrenergic effect (32%)], 8.9%
Figure 1 Electrocardiograms showing loss of R wave progression and T wave inversions in the anterior leads. EKG at presentation (A) showing a
left anterior fascicular block de novo, besides the complete right bundle branch block already present. The 30-min EKG (B) evolving with inversion of
V1-V6 wave and the 1 hour EKG showing deep T wave inversion and loss of R wave in all precordial leads (C).
Figure 2 Left ventriculogram of patient in diastole (panel A) and systole (panel B) showing persistent mid-apical left ventricular akinesia with hyper-
kinesis of the remaining basal walls.





















































..had a probable vasospastic aetiology, and in a significant percentage
(20.4%) of the cases it was not possible to determine the most likely
pathophysiological mechanism.
Although the pathophysiology of TS in the present case remains
unconfirmed, we cannot exclude a possible role of a cardiotoxic ef-
fect of omalizumab in a predisposed patient with reduced oestrogen
levels.
Even though it is rare, there are some reported cases of anaphyl-
actic reactions following chronic administration of omalizumab. Price
and Hamilton22 have most likely hypothesized an anaphylactic reac-
tion to an omalizumab excipient—polysorbate. Coors et al.23
attempted to explain a case of anaphylaxis secondary to polysorbate
and failed to demonstrate an immune response secondary to poly-
sorbate but proved that this substance was capable of inducing mast
cell degranulation.
Thus, in the present case, even though an anaphylactic reaction did
not take place, the pathophysiological mechanism could be explained
by a polysorbate-mediated mast cell degranulation with the release
of mediators such as histamine, norepinephrine, epinephrine, which
are inducers of coronary spasm.24
Besides that, it is not possible to exclude a cross-link omalizumab-
specific IgG bound to macrophages through low-affinity receptor
(FcRIII). The large antigen load afforded by the 300-mg injection may
have been enough to cross-link omalizumab-specific IgG bound to
macrophages through low-affinity FcRIII, causing the activation and
degranulation of the mastocytes.
The fact that serum and urinary cathecolamine levels were normal
may be due to the short half-life of these circulating hormones that
can be degraded before evaluation of the hormones.
When applying the Naranjo scale25 to our case, which assesses the
likelihood of an adverse drug reaction, the causality between the
administration of omalizumab and the development of TS is classified
as possible (three points).
At a time when monoclonal antibodies have an increasing range of
indications and are in exponential use, it is of crucial importance to
maintain adequate pharmacovigilance in order to detect at an early
stage potential adverse drug effects.
Conclusion
This is the first case described in the literature of TS after administra-
tion of omalizumab. As the aetiopathogenesis of TS is still under de-
bate and the pathophysiology link with many drugs’ side effects
remain to be investigated, this case may provide valuable insights into
the pathogenesis of TS. As our knowledge grows, the list of possible
TS triggers may also grow. More TS reported cases and thorough
registries are needed to better describe the triggers and to better
understand this syndrome.
Supplementary material
Supplementary material is available at European Heart Journal - Case
Reports online.
Slide sets: A fully edited slide set detailing this case and suitable for
local presentation is available online as Supplementary data.
Consent: The authors confirm that written consent for submis-
sion and publication of this case report including image(s) and
associated text has been obtained from the patients in line with
COPE guidance.
Figure 3 MIBG scintigraphy showing the heart/mediastinum ratio of 1.55 (A) and decreased myocardial 123I-MIBG uptake in the lateral, inferolat-
eral, and apical walls (B).
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